Chandigarh

CSIR-INSTITUTE OF MICROBIAL TECHNOLOGY ORGANIZES IMTECHCON 2.0 WITH FOCUS ON BIOLOGICAL DRUG TECHNOLOGIES.

December 10, 2018 08:09 PM

Chandigarh (JS Kaler)

CSIR-Institute of Microbial Technology (IMTECH), a premier microbial institute under the aegis of Ministry of Science and Technology, Government of India, today organized an one day conference IMTechCon 2.0 BiotheraP 2018. IMTechCon 2.0 as the name suggests is the extension of our first IMTECHCon, organized last year.

The aim of this meeting is to engage industry and academic leaders to discuss the frontiers and current challenges in biotherapeutics & biochemical engineering, fermentation technology & downstream process in biological and biopharmaceuticals in Indian and global scenario. 

The conference was presided over by Sh. J.M. Balamurugan, IAS, who suggested that such close interactions shall pave path to forge new R & D partnership and alliances between industry and research Institutions. Also present on this occasion were Dr. Rajesh S. Gokhale, National Institute of Immunology, New Delhi along with Dr. Maharaj Sahib, Director, Genomics & Biotechnology, Wockhardt Ltd., Aurangabad and Dr. Venkata Ramanna, CSO, Reliance Life Sciences Pvt. Ltd Mumbai.   

The conference was presided over by Sh. J.M. Balamurugan, IAS, who suggested that such close interactions shall pave path to forge new R & D partnership and alliances between industry and research Institutions. Also present on this occasion were Dr. Rajesh S. Gokhale, National Institute of Immunology, New Delhi along with Dr. Maharaj Sahib, Director, Genomics & Biotechnology, Wockhardt Ltd., Aurangabad and Dr. Venkata Ramanna, CSO, Reliance Life Sciences Pvt. Ltd Mumbai.   

In what is being termed as a biggest confidence building measure exercise with industry in area of Biotherapeutics and Biochemical Engineering, IMTechCon 2.0 witnessed nearly a dozen speakers and panelists present their ideas and views to the scientific community. Distinguished panel of speakers at IMTechCon 2.0 included speakers from Serum Institute, Wockhardt Ltd., Reliance Life Sciences, Serum Institute, Yashraj Biotechnologies and many others. Director CSIR-IMTECH, Dr. Anil Koul, welcomed the dignitaries and mentioned that CSIR-IMTECH has already striven to live upto the Govt’s expectations, and its achievements in various spheres are being recognized at the National and International levels. He also presented the new mandate of the institute focusing on Technology Area Platforms and being Disease Area Specific.   

Speaking on the occasion Sh. J.M. Balamurugan, IAS and Secretary to the Hon’ble Governor of Punjab said the challenges in healthcare are humongous and are even more in the under-privileged sections of our society. He further said that the challenges are outpacing the solutions being developed. The need of the hour is to embark upon collaboration between Industry and R&D institutes, which is a cost effective strategy offering faster results. He stressed that the scientist fraternity should embark upon projects of human welfare with a holistic approach.   

Dr. Rajesh Gokhale ex-Director CSIR- IGIB, currently working as a scientist at National Institute of Immunology, New Delhi delivered a talk titled “Need for Innovation in Pharma” and highlighted the need of evidence based scientific intervention and to define the standard of care in clinical practices. He also strongly advocated that offering treatment of the symptoms and not getting to the root cause of the disease may create more complications than curing the disease.   

Dr. Maharaj Sahib, Director, Genomics & Biotechnology, Wockhardt Ltd., Aurangabad During his talk the pathway for development of recominant therapeutic protein from gene to vial/cartridge/pen was presented with opportunities and challenges including regulatory challenges for marketing a bioteherapeutic in developed markets. Wockhardt’s contribution has been that it was the first company to launch recombinant human insulin, Recombinant insulin glargine and recombinant human erythropoietin  and other products India. He further apprised that IMTECH has the insfrastructure and faculty to build upon opportunities to revolutinize healthcare and create knowledge based employment growth.   

Dr. Venkata Ramana, CSO, Reliance Life Sciences Pvt. Ltd., Mumbai spoke on biologics offering solutions for the treatment of various diseases including cancer and auto-immune diseases. Some aspects of early development of biologics were also discussed in his talk.  

Dr. S.K. Jana, Additional Director, Serum Institute, Pune delivered a very information talk on the cost effective pneumococcal conjugate vaccine for the treatment of pneumoccal diseaases. This is in alignment with Prime Minister’s “Make in India” initiative.  

Dr. Paresh Bhanushali, Co-Founder Yashraj Biotechnologies, Navi Mumbai discussed on having a positive approach from an academic instutitute with industry. GMP setup within institute will help industry to do initial work in the development of biosimilars and biologics. One aspect is to suggest in working with diagnostic industry to develop platform technologies, which the country is currently relying on MNC’s. 

Dr. Rahul Bhambure, Senior Scientist from CSIR-NCL, Pune discussed the understanding of in vitro and in vivo refolding of antibody fragment therapeutics. The design of protocol may help in time and cost effective production of antibody fragments.

IMTechCon 2.0 was well attended and well received. Several students and researchers from various Institutions attended the meet and visited the labs of the Institute to know about the research being carried out at this premier national lab.   

The Institute of Microbial Technology (IMTech), Sector 39-A, Chandigarh is a national centre for excellence in microbial sciences established in 1984. IMTech vision is to discover and develop translational products and new drugs to address key unmet medical needs.

Have something to say? Post your comment
Copyright © 2017, Face 2 News, All rights reserved. Terms & Conditions Privacy Policy Disclaimers